GIVASTOMIG

UNII:	8MSM5N7RMK
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	GIVASTOMIG
GSRS Full Record:	8MSM5N7RMK i

2762499-30-7
Fused G1-scFv lambda-heavy chain humanized (1-716) [gamma1 heavy chain anti-CLDN18 humanized (1-450) [VH (Homo sapiens IGHV1-3*01 (85.7%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120)-Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14, IGHG1v29 CH2 A84.4 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>A (300) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)] -15-mer tris(tetraglycyl-seryl) linker (451-465) -scFv lambda-heavy anti-TNFRSF9 humanized, scFv-v2 C120 (VL)-C49 (VH) (466-716) [V-LAMBDA (Homo sapiens IGLV1-47*02 (91.8%) -IGLJ2*01 (90.9%), C120 (568), CDR-IMGT [8.3.11] (491-498.516-518.555-565)) (466-575) -20-mer tetrakis(tetraglycyl-seryl) linker (576-595) -VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (100%), C49 (639), CDR-IMGT [8.8.14] (621-628.646-653.692-705)) (596-716)]]; (223-220')-disulfide with kappa light chain anti-CLDN18 humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (88.1%) -IGKJ2*01 (91.7%) Q120>G (106'), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (159'), V101 (197') (114'-220')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, non-glycosylated
Givastomig
Givastomig [WHO-DD]
Immunoglobulin G1 [300-alanine], anti-(claudin CLDN18.2) (human-Mus musculus γ1-chain) fusion protein with peptide linker ((GGGGS)3) fusion protein with immunoglobulin anti-(tumor necrosis factor receptor TNFRSF9) (human-Mus musculus single-chain variable fragment VL-(GGGGS)4-VH), disulfide with human κ-chain, dimer
Immunoglobulin G1-scFv_L-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J)isoform 2, extracellular domain 1 (EC1)], anti-[Homo sapiens TNFRSF9 (TNF receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], humanized monoclonal antibody, bispecific, agonist
givastomig [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

GIVASTOMIG

Synonyms and Mappings

Resources